These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

217 related articles for article (PubMed ID: 35890409)

  • 1. Development of a Personalized Tumor Neoantigen Based Vaccine Formulation (FRAME-001) for Use in a Phase II Trial for the Treatment of Advanced Non-Small Cell Lung Cancer.
    Oosting LT; Franke K; Martin MV; Kloosterman WP; Jamieson JA; Glenn LA; de Jager MW; van Zanten J; Allersma DP; Gareb B
    Pharmaceutics; 2022 Jul; 14(7):. PubMed ID: 35890409
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Personalized neoantigen vaccine enhances the therapeutic efficacy of bevacizumab and anti-PD-1 antibody in advanced non-small cell lung cancer.
    Lin X; Tang S; Guo Y; Tang R; Li Z; Pan X; Chen G; Qiu L; Dong X; Zhang L; Liu X; Cai Z; Xie B
    Cancer Immunol Immunother; 2024 Jan; 73(2):26. PubMed ID: 38280084
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Personalized therapy with peptide-based neoantigen vaccine (EVX-01) including a novel adjuvant, CAF®09b, in patients with metastatic melanoma.
    Mørk SK; Kadivar M; Bol KF; Draghi A; Westergaard MCW; Skadborg SK; Overgaard N; Sørensen AB; Rasmussen IS; Andreasen LV; Yde CW; Trolle T; Garde C; Friis-Nielsen J; Nørgaard N; Christensen D; Kringelum JV; Donia M; Hadrup SR; Svane IM
    Oncoimmunology; 2022; 11(1):2023255. PubMed ID: 35036074
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Personal Neoantigens From Patients With NSCLC Induce Efficient Antitumor Responses.
    Zhang W; Yin Q; Huang H; Lu J; Qin H; Chen S; Zhang W; Su X; Sun W; Dong Y; Li Q
    Front Oncol; 2021; 11():628456. PubMed ID: 33928024
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Neoantigen identification strategies enable personalized immunotherapy in refractory solid tumors.
    Chen F; Zou Z; Du J; Su S; Shao J; Meng F; Yang J; Xu Q; Ding N; Yang Y; Liu Q; Wang Q; Sun Z; Zhou S; Du S; Wei J; Liu B
    J Clin Invest; 2019 May; 129(5):2056-2070. PubMed ID: 30835255
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Personalized neoantigen vaccine NEO-PV-01 with chemotherapy and anti-PD-1 as first-line treatment for non-squamous non-small cell lung cancer.
    Awad MM; Govindan R; Balogh KN; Spigel DR; Garon EB; Bushway ME; Poran A; Sheen JH; Kohler V; Esaulova E; Srouji J; Ramesh S; Vyasamneni R; Karki B; Sciuto TE; Sethi H; Dong JZ; Moles MA; Manson K; Rooney MS; Khondker ZS; DeMario M; Gaynor RB; Srinivasan L
    Cancer Cell; 2022 Sep; 40(9):1010-1026.e11. PubMed ID: 36027916
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Preliminary clinical study of personalized neoantigen vaccine therapy for microsatellite stability (MSS)-advanced colorectal cancer.
    Yu YJ; Shan N; Li LY; Zhu YS; Lin LM; Mao CC; Hu TT; Xue XY; Su XP; Shen X; Cai ZZ
    Cancer Immunol Immunother; 2023 Jul; 72(7):2045-2056. PubMed ID: 36795124
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Personalized neoantigen-based immunotherapy for advanced collecting duct carcinoma: case report.
    Zeng Y; Zhang W; Li Z; Zheng Y; Wang Y; Chen G; Qiu L; Ke K; Su X; Cai Z; Liu J; Liu X
    J Immunother Cancer; 2020 May; 8(1):. PubMed ID: 32439798
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Beyond Sequencing: Prioritizing and Delivering Neoantigens for Cancer Vaccines.
    Roesler AS; Anderson KS
    Methods Mol Biol; 2022; 2410():649-670. PubMed ID: 34914074
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effective personalized neoantigen vaccine plus anti-PD-1 in a PD-1 blockade-resistant lung cancer patient.
    Gao S; Wang J; Zhu Z; Fang J; Zhao Y; Liu Z; Qin H; Wei Y; Xu H; Dan X; Yang L; Xu Q
    Immunotherapy; 2023 Feb; 15(2):57-69. PubMed ID: 36651232
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison of personal and shared frameshift neoantigen vaccines in a mouse mammary cancer model.
    Peterson M; Murphy SN; Lainson J; Zhang J; Shen L; Diehnelt CW; Johnston SA
    BMC Immunol; 2020 May; 21(1):25. PubMed ID: 32370785
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Small-scale manufacturing of neoantigen-encoding messenger RNA for early-phase clinical trials.
    Ingels J; De Cock L; Mayer RL; Devreker P; Weening K; Heyns K; Lootens N; De Smet S; Brusseel M; De Munter S; Pille M; Billiet L; Goetgeluk G; Bonte S; Jansen H; Lint SV; Leclercq G; Taghon T; Menten B; Vermaelen K; Impens F; Vandekerckhove B
    Cytotherapy; 2022 Feb; 24(2):213-222. PubMed ID: 34696961
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comprehensive mutanome analysis of Lewis lung cancer reveals immunogenic neoantigens for therapeutic vaccines.
    Chen T; Hu R; Wan Y; Sun F; Wang Z; Yue J; Chen J; Han G; Wei G; Dong Z
    Biochem Biophys Res Commun; 2020 May; 525(3):607-613. PubMed ID: 32115148
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A Phase I/II trial comparing autologous dendritic cell vaccine pulsed either with personalized peptides (PEP-DC) or with tumor lysate (OC-DC) in patients with advanced high-grade ovarian serous carcinoma.
    Sarivalasis A; Boudousquié C; Balint K; Stevenson BJ; Gannon PO; Iancu EM; Rossier L; Martin Lluesma S; Mathevet P; Sempoux C; Coukos G; Dafni U; Harari A; Bassani-Sternberg M; Kandalaft LE
    J Transl Med; 2019 Nov; 17(1):391. PubMed ID: 31771601
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Epidermal Growth Factor Receptor-Targeted Neoantigen Peptide Vaccination for the Treatment of Non-Small Cell Lung Cancer and Glioblastoma.
    Li F; Wu H; Du X; Sun Y; Rausseo BN; Talukder A; Katailiha A; Elzohary L; Wang Y; Wang Z; Lizée G
    Vaccines (Basel); 2023 Sep; 11(9):. PubMed ID: 37766136
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Neoantigen Cancer Vaccines: Generation, Optimization, and Therapeutic Targeting Strategies.
    Reynolds CR; Tran S; Jain M; Narendran A
    Vaccines (Basel); 2022 Jan; 10(2):. PubMed ID: 35214655
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Personalized Neoantigen-Pulsed DC Vaccines: Advances in Clinical Applications.
    Tang L; Zhang R; Zhang X; Yang L
    Front Oncol; 2021; 11():701777. PubMed ID: 34381724
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Neoantigen vaccine platforms in clinical development: understanding the future of personalized immunotherapy.
    Supabphol S; Li L; Goedegebuure SP; Gillanders WE
    Expert Opin Investig Drugs; 2021 May; 30(5):529-541. PubMed ID: 33641576
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Neoantigen-based personalized cancer vaccines: the emergence of precision cancer immunotherapy.
    Richard G; Princiotta MF; Bridon D; Martin WD; Steinberg GD; De Groot AS
    Expert Rev Vaccines; 2022 Feb; 21(2):173-184. PubMed ID: 34882038
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cancer Neoantigens: Challenges and Future Directions for Prediction, Prioritization, and Validation.
    Borden ES; Buetow KH; Wilson MA; Hastings KT
    Front Oncol; 2022; 12():836821. PubMed ID: 35311072
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.